<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02144272</url>
  </required_header>
  <id_info>
    <org_study_id>15098</org_study_id>
    <secondary_id>I6W-MC-TNAA</secondary_id>
    <nct_id>NCT02144272</nct_id>
  </id_info>
  <brief_title>Safety Study to Evaluate LY3114062 in Participants With Inflammatory Arthritis</brief_title>
  <official_title>A Phase 1 Single-Dose, Dose Escalation Study to Evaluate the Safety and Tolerability of LY3114062 in Subjects With Inflammatory Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to learn more about the safety of LY3114062 and to find out
      how well it is tolerated in participants with an inflammatory arthritis. The study will also
      investigate how the body processes the drug and how the drug affects inflammatory arthritis.
      The study is expected to last about 3 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Participants with One or More Drug-Related Adverse Events</measure>
    <time_frame>Baseline to study completion (3 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Plasma Concentration (Cmax) of LY3114062</measure>
    <time_frame>Predose through Day 85, at specified timepoints</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration-time curve (AUC) of LY3114062</measure>
    <time_frame>Predose through Day 85, at specified timepoints</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Production Against LY3114062</measure>
    <time_frame>Day 1, 8, 15, 29, 85 and early discontinuation</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Inflammatory Arthritis</condition>
  <arm_group>
    <arm_group_label>LY3114062 (SC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3114062 given as a single subcutaneous (SC) dose, in escalating dose cohorts starting at 2 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3114062 (IV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3114062 given once intravenous (IV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (sodium chloride injection) given as a single SC dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3114062 SC</intervention_name>
    <description>LY3114062 administered SC.</description>
    <arm_group_label>LY3114062 (SC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered SC.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3114062 IV</intervention_name>
    <description>LY3114062 administered IV.</description>
    <arm_group_label>LY3114062 (IV)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signs or symptoms of an inflammatory arthritis for a duration of at least 8 weeks at
             screening.

          -  Presence of at least 3 out of 66 swollen joints at screening and baseline, as
             determined by the swollen joint count assessment forms.

        Exclusion Criteria:

          -  Synthetic disease-modifying antirheumatic drugs DMARD use as follows:

               -  ANY treatment with tofacitinib within 28 days prior to baseline or planned
                  treatment with tofacitinib during the study;

               -  Treatment with other synthetic DMARDs (eg, hydroxychloroquine, methothrexate,
                  leflunomide, sulfasalazine, and gold salts) at an unstable dose within 28 days
                  prior to baseline or if the dose of drug is planned to be changed during the
                  study.

          -  Previous treatment with marketed biologic DMARDs as follows:

               -  Etanercept, adalimumab, or anakinra &lt;4 weeks prior to baseline;

               -  Infliximab, certolizumab pegol, golimumab, abatacept, or tocilizumab &lt;8 weeks
                  prior to baseline;

               -  Rituximab &lt;12 months prior to baseline

        Note: Other biologic agents for indications other than an inflammatory arthritis may be
        allowed after discussion with the sponsor

          -  Treatment with &gt;10 mg/day, or unstable dose, of oral prednisone or equivalent within
             28 days prior to baseline.

          -  Confirmed or suspected septic arthritis, crystal arthropathy, systemic lupus
             erythematosus, reactive arthritis, or certain other rheumatic conditions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM-5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chisinau</city>
        <zip>MD2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bucharest</city>
        <zip>50159</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Georgia</country>
    <country>Moldova, Republic of</country>
    <country>Romania</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2014</study_first_submitted>
  <study_first_submitted_qc>May 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2014</study_first_posted>
  <last_update_submitted>July 15, 2015</last_update_submitted>
  <last_update_submitted_qc>July 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibody</keyword>
  <keyword>Tumor Necrosis Factor alpha</keyword>
  <keyword>Interleukin-17</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

